As per MRFR analysis, the China Ophthalmic Drugs and Devices Market Size was estimated at 3.44 (USD Billion) in 2023. The China Ophthalmic Drugs and Devices Market is expected to grow from 3.75 (USD Billion) in 2024 to 18.75 (USD Billion) by 2035. The China Ophthalmic Drugs and Devices Market CAGR (growth rate) is expected to be around 15.756% during the forecast period (2025 - 2035).
Marked growth in the China ophthalmic drugs and devices market is being fueled by the rising rates of eye related diseases like myopia and glaucoma, particularly in the elderly. There is a focus on overall improvement in the health care sector at a national level, which also includes treating and improving ophthalmologic services.
The reforms put in place from within the state are easier for drugs to be approved, which in turn facilitates newer inventions within the field of Ophthalmology. This is accompanied by a heightened demand towards consumer education on eye care highlighting the significance of routine eye examinations, creating a greater scope for both preventive and corrective measures for eye disorders.
The digital health technology field has its opportunities. With the growth of telemedicine and mobile health applications, access to eye care is improving in China, especially in underserved regions.
Moreover, enhanced local investments are expected to improve the product portfolios of local pharmaceutical companies and expedite the introduction of international ophthalmic products. Emerging trends also include increased investment in R&D that is greatly supported by the Chinese government to foster healthcare innovation.
There is currently a boom in the Chinese market for investment aimed at developing advanced therapies, such as smart contact lenses, and advanced surgical tools that are less invasive.
The use of advanced equipment by the hospitals and specialty clinics has increased, which is aided by easier financing and improved reimbursement policies. This helps foster the growth of drugs and devices within the ophthalmic market in China. This environment will continue to adapt as technology and healthcare needs of the population advance quickly.
The rising prevalence of eye-related disorders, particularly among the aging population in China, is significantly driving the China Ophthalmic Drugs and Devices Market. According to the National Health Commission of China, it was reported that by 2025, the number of individuals aged 60 and above will exceed 300 million.
This demographic shift has led to higher cases of age-related macular degeneration and glaucoma, compelling a substantial need for improved treatments and devices. Major pharmaceutical companies such as Novartis and Roche are expanding their portfolios in the ophthalmic sector to address these growing demands.
Furthermore, with the World Health Organization highlighting that uncorrected refractive errors affect nearly 600 million people globally, the urgency to develop effective ophthalmic solutions in China is apparent, making significant investments in Research and Development (R&D) crucial for capturing this booming market.
Rapid technological advancements in ophthalmic devices are substantially influencing the growth of the China Ophthalmic Drugs and Devices Market. Innovations such as minimally invasive surgical techniques and the incorporation of artificial intelligence in diagnostics have transformed the landscape.
For instance, the China Food and Drug Administration has approved numerous advanced devices over the past few years. Companies like Johnson & Johnson and Alcon have launched state-of-the-art surgical equipment and diagnostic tools that improve patient outcomes.
With the National Medical Products Administration promoting faster approvals for innovative devices, it has become easier for companies to introduce their high-tech solutions into the market, thus driving sales and market growth.
The Chinese government's initiatives and healthcare reforms aimed at enhancing healthcare infrastructure are major factors fueling the growth of the China Ophthalmic Drugs and Devices Market. The Healthy China 2030 initiative launched by the Chinese government emphasizes improved healthcare access and quality.
Reports indicate that healthcare expenditure is set to increase significantly, with the government aiming to boost the health sector budget by approximately 30% over the next decade. This has led to increased funding for vision care, enabling hospitals to procure advanced ophthalmic drugs and devices.
Leading healthcare providers, such as Beijing Tongren Hospital, have already reported improvements in their eye care services due to these reforms, which enhances market prospects.
The China Ophthalmic Drugs and Devices Market is experiencing considerable growth, driven by increasing prevalence of eye disorders and greater awareness regarding eye health among the population. In this market, the Product segment comprises primarily of two critical areas: Drugs and Devices.
The Drugs category includes therapeutic solutions aimed at treating various eye conditions such as glaucoma, dry eye syndrome, and age-related macular degeneration. This segment is significant as it plays a vital role in enhancing patients' quality of life, and is witnessing a surge in demand due to the aging population, which is increasingly susceptible to eye diseases.
Meanwhile, the Devices segment encompasses a range of surgical instruments, diagnostic equipment, and vision correction products, which are essential for providing comprehensive eye care. This segment dominates the market given the advancements in technology, leading to the development of more effective and minimally invasive procedures.
The growing adoption of innovative technologies, such as telemedicine and augmented reality in surgical procedures, further enhances the potential of the Devices segment. The Chinese government, recognizing the rise in eye-related health issues, is investing in health initiatives that promote better access to both drugs and devices, which is likely to foster market growth.
Overall, the Product segment in the China Ophthalmic Drugs and Devices Market is characterized by continuous innovation, increasing investment in Research and Development, and a robust pipeline of new therapies and devices, which collectively are expected to address the growing health needs of the population.
The Treatment segment of the China Ophthalmic Drugs and Devices Market is characterized by its diverse therapeutic areas, addressing critical issues affecting visual health. Eye Infections, for instance, represent a significant portion of treatment needs due to rising incidences linked to pollution and lifestyle changes in urban areas.
Allergic Conjunctivitis is also prevalent, driven by increasing pollution levels and allergens in the environment, requiring effective management solutions to alleviate symptoms. Dry Eyes Syndrome has emerged as a major concern, particularly among professionals engaged in extensive screen time, leading to a greater need for lubricating eye drops and innovative treatments.
Red Eyes can stem from various underlying conditions, highlighting the importance of comprehensive treatment methodologies. Inflammation-related cases are growing, necessitating targeted anti-inflammatory therapies that address specific ocular conditions.
Each of these areas not only reflects a critical healthcare requirement but also emphasizes the importance of ongoing Research and Development, government support for healthcare initiatives, and rising awareness regarding eye health in China. The segment is poised for growth as awareness and treatment accessibility continue to expand across urban and rural settings.
The competitive landscape of the China Ophthalmic Drugs and Devices Market is characterized by rapid growth and a dynamic environment, driven by increasing incidences of eye-related disorders and a burgeoning aging population. The market comprises a diverse portfolio of products which includes pharmaceutical drugs for the treatment of various eye conditions as well as advanced surgical devices and diagnostic equipment.
This sector is highly regulated, with companies continually striving to innovate and adapt to changing healthcare regulations and patient needs. Competitor activity remains intense as organizations focus on differentiating their offerings through technology integration, improved patient outcomes, and cost-effectiveness. The drive for market expansion is fueled by strategic partnerships, mergers and acquisitions, and increased investment in research and development to better leverage emerging opportunities within the Chinese healthcare landscape.
Carl Zeiss AG has a significant presence in the China Ophthalmic Drugs and Devices Market, leveraging its robust heritage in optical systems and design to supply high-quality products. The company enjoys a strong reputation for its precision instruments and innovative ophthalmic solutions, including advanced diagnostic devices and surgical technologies.
With a commitment to maintaining a competitive edge, Carl Zeiss AG continuously invests in research and development, enabling them to introduce cutting-edge equipment that enhances clinical efficacy and patient safety. Their strengths lie in their expansive distribution network and strong relationships with healthcare providers, ensuring that their products are accessible in various regions across China.
This focus on quality and innovation has allowed Carl Zeiss AG to establish itself as a leader in the ophthalmic market within the country.
Allergan operates prominently within the China Ophthalmic Drugs and Devices Market, offering a diverse range of products aimed at various ocular conditions. The company is particularly recognized for its advancements in therapies for conditions such as glaucoma and dry eye syndrome, along with surgical innovations.
Allergan has fostered a strong brand presence through its comprehensive approach in tackling eye health issues and remains committed to developing new treatments that cater to the specific needs of Chinese patients. The company's strengths include not only its beloved product offerings but also its active role in local partnerships, enabling them to enhance their market approach through collaborations and strategic alliances.
Additionally, Allergan is known for its continued investments in expanding its product portfolio and enhancing its market penetration strategies, further solidifying its influence and competitive edge within the Chinese ophthalmic landscape. Mergers and acquisitions have played a crucial role for Allergan in fortifying its capabilities and market presence, thus ensuring its resilience and adaptability in this ever-evolving sector.
Recent developments in the China Ophthalmic Drugs and Devices Market have been marked by significant advancements and investments. Companies such as Carl Zeiss AG and Alcon have been increasing their presence through innovative product launches and partnerships aimed at addressing the rising demand for eye care solutions in urban areas.
In September 2023, Hoya Corporation announced new technologies to enhance intraocular lens offerings, while Regeneron Pharmaceuticals recently gained traction with its EYLEA drug, which is seeing growing usage among ophthalmologists. Notably, in July 2023, AbbVie completed its acquisition of Allergan, positioning itself to offer a broader suite of ophthalmic treatments in China, fostering competitive dynamics.
The market is projected to grow significantly, driven by an aging population and rising incidences of refractive errors. Additionally, Novartis and Roche are focusing on expanding their research and development efforts in China, aiming to innovate treatment options amid increasing healthcare expenditure.
Over the last few years, investments in telemedicine for eye care have surged, and regulatory support from the Chinese government promotes faster approvals of new drugs and devices, further stimulating market growth.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 2.06(USD Billion) |
| MARKET SIZE 2024 | 2.25(USD Billion) |
| MARKET SIZE 2035 | 11.25(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.756% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Santen, Pfizer, Alcon, Merck, Bayer, Roche, Genentech, Johnson & Johnson, Hoya, Regeneron, Eagle Pharmaceuticals, Ophthotech, Bausch Health, AbbVie, Novartis |
| SEGMENTS COVERED | Product, Treatment |
| KEY MARKET OPPORTUNITIES | Aging population driving demand, Increasing prevalence of eye diseases, Growth in telemedicine for eye care, Advancements in surgical techniques, Rising awareness of eye health |
| KEY MARKET DYNAMICS | aging population, increasing prevalence of eye diseases, technological advancements in devices, growing healthcare expenditure, rising awareness and access |
| COUNTRIES COVERED | France |
Frequently Asked Questions (FAQ) :
In 2024, the France Ophthalmic Drugs and Devices Market is expected to be valued at 2.25 billion USD.
By 2035, the market is anticipated to reach a value of 11.25 billion USD.
The market is expected to grow at a CAGR of 15.756% from 2025 to 2035.
The market is segmented into drugs and devices, with drugs valued at 0.9 billion USD and devices at 1.35 billion USD in 2024.
The drugs segment is projected to be valued at 4.5 billion USD by 2035.
The devices segment is expected to reach a value of 6.75 billion USD by 2035.
Major players include Santen, Pfizer, Alcon, Merck, Bayer, Roche, Genentech, Johnson & Johnson, Hoya, Regeneron, and AbbVie.
Growth drivers include increasing prevalence of eye diseases and advancements in ophthalmic treatment technologies.
Emerging trends include a focus on personalized medicine and innovative drug delivery systems.
The ongoing global scenario may influence supply chains and affect the market dynamics for ophthalmic products.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
